<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 11 patients who had <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia-chromosome-positive</z:e> <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> with natural interferon alpha (human lymphoblastoid interferon; HLBI) </plain></SENT>
<SENT sid="1" pm="."><plain>HLBI was given at 6-12 X 10(6) u/day i.m. or i.s.c. during induction therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Nine patients responded to the treatment, of whom 7 had hematologic remission and 2 had partial remission </plain></SENT>
<SENT sid="3" pm="."><plain>Six patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or hypoplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and 3 patients with overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with recombinant interferon gamma (GI-3) </plain></SENT>
<SENT sid="4" pm="."><plain>GI-3 was given at 0.4 X 10(6) u/m2 of body-surface area per day i.s.c. or i.v. for 4-6 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>In 2 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and hypoplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, the blast cell count in bone marrow decreased from 8-16% to 2-3% after 4 weeks of administration </plain></SENT>
<SENT sid="6" pm="."><plain>In another patient with hypoplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, blast cells in the marrow did not decrease, but <z:hpo ids='HP_0001903'>anemia</z:hpo> was improved without transfusion, increasing the bone marrow NCC and erythroblast count </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, no clinical effect was obtained </plain></SENT>
<SENT sid="8" pm="."><plain>Interferons can therefore be offered to patients in a preleukemic state </plain></SENT>
</text></document>